SGLT2 Inhibitors and Hemoglobin Improvement in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Mechanistic Rationale and Emerging Clinical Evidence
Anemia · 2026-01 · 2026 (1)
DOI: 10.1155/anem/4918154 ↗Abstract
Anemia represents one of the most clinically significant and therapeutically challenging complications in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), particularly in myelofibrosis. It is associated with increased symptom burden, transfusion dependence, and reduced overall survival. Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have consistently demonstrated increases in hemoglobin levels across multiple large randomized clinical trials in cardiovascular, renal, and metabolic diseases, raising interest in their potential role as modulators of erythropoiesis. This narrative review aimed to provide a comprehensive and mechanistically grounded overview of the role of SGLT2 inhibitors in improving hemoglobin levels in patients with MDS and MPN. A literature review was conducted using PubMed, Embase, and Google Scholar, focusing on the database from inception to June 2026. Studies evaluating SGLT2 inhibitors and hematologic outcomes in MDS, MDS/MPN overlap syndromes, myelofibrosis, or other MPNs were included. Both clinical and mechanistic studies were included. Current evidence in MDS and MPN remains limited to small observational cohorts, retrospective studies, and case reports. Across the available clinical studies in patients with MDS and MPN, SGLT2 inhibitors were associated with increases in hemoglobin, generally ranging from 1.0 to 1.6 g/dL. Specifically, a median peak hemoglobin increase of approximately 1.2 g/dL was reported among non‐transfusion‐dependent patients with MDS/MDS‐MPN overlap receiving SGLT2 inhibitors, while patients with myelofibrosis receiving predominantly empagliflozin or dapagliflozin had a median increase of 1.0 g/dL. In MDS and myelofibrosis, these findings may reflect improvement in ineffective erythropoiesis, whereas in non‐anemic MPN subtypes, the observed changes may instead represent erythrocytosis. Preliminary observational findings suggest a potential erythropoietic effect of SGLT2 inhibitors; however, whether this translates into a therapeutic benefit in MDS or MPN remains uncertain and requires prospective and mechanistic validation.
EUVIMED